DNA Repair Drugs Segment is Fastest Growing Segment Fueling the Growth of Dna Repair Drugs Market
Dna repair drugs are used to treat genetic disorders caused due to errors in dna repair mechanisms. These drugs help in rectifying errors in dna strands and sequences thereby helping in treating complex conditions like cancer and genetic disorders. Their ability to repair damaged dna and restore proper dna functioning makes them highly effective therapeutic agents.
The
global Dna Repair Drugs Market is estimated to be valued at US$ 6.28 Bn in 2023
and is expected to exhibit a CAGR of
6.5% over the forecast period 2023 to 2030, as highlighted in a new report
published by Coherent Market Insights.
Market key trends:
One of the major trends driving the growth of the dna repair drugs market is
the increasing incidence of cancer worldwide. According to WHO, cancer burden
has risen to 18.1 million new cases and 9.6 million deaths in 2018. The four
main types of cancer with highest incidents being lung, breast, colon and
prostate cancer. DNA repair pathways play a critical role in preventing cancer
formation. Malfunctions in DNA repair pathways leads to accumulation of DNA
damage which drives the cancer development and progression. Therefore,
effective DNA repair drugs are developed which target specific DNA repair
pathways dysfunctional in cancer cells thereby inhibiting tumor growth and
progression.
Segment Analysis
The global
DNA repair drugs market size is segmented into directed drugs, and
organic small molecules. The directed drugs segment dominated the market in
2022 and is expected to continue its dominance over the forecast period owing
to the availability of drugs like Polynucleotide kinase 3'-phosphatase (PNKP),
XRCC1, and PARP inhibitors that are specifically directed towards repairing
DNA.
Key Takeaways
The global DNA repair drugs market is expected to witness high growth,
exhibiting CAGR of 6.5% over the forecast period, due to increasing incidence
of cancer globally.
Regional analysis
North America dominated the global market in 2022 and is expected to continue
its dominance over the forecast period. This is attributed to the growing
prevalence of cancer and rising healthcare spending in the region. Asia Pacific
is expected to witness the highest growth rate over the forecast period owing
to rising cancer incidence, growing awareness regarding cancer treatment, and
increasing healthcare expenditure in the region.
Key players
Key players operating in the DNA repair drugs market are AbbVie Inc., Amgen
Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co.,
F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson
& Johnson, Merck & Co., Inc., Merck KGAA, Novartis AG, Pfizer Inc., and
Sanofi S.A.
Get more insights on this topic: https://www.newsstatix.com/dna-repair-drugs-market-share-and-opportunity-analysis-2023-2030/
Comments
Post a Comment